Research Progress on Traditional Chinese Medicine Treatment of Nonalcoholic Fatty Liver Based on NF-κB Signaling Pathway
- VernacularTitle:基于NF-κB信号通路探讨中药治疗非酒精性脂肪肝研究进展
- Author:
Congyi LIU
1
;
Na ZHENG
;
Jingjing XU
;
Ning WANG
;
Zimeng HUANG
;
Ying DING
;
Lingling QIN
;
Lili WU
;
Tonghua LIU
Author Information
- Publication Type:Journal Article
- Keywords: Traditional Chinese medicine; Non-alcoholic fatty liver disease; NF-κB; Signaling pathway
- From: World Science and Technology-Modernization of Traditional Chinese Medicine 2025;27(9):2553-2568
- CountryChina
- Language:Chinese
- Abstract: Non-alcoholic fatty liver disease(NAFLD)is a progressive liver disease caused by factors other than alcohol caused by heterotopic fat accumulation in the liver.In recent years,the incidence rate has been increasing,and there is no specific clinical drug.Studies have found that nuclear transcription factor κB(NF-κB)can activate inflammation and oxidative stress,which plays an important role in the pathogenesis of NAFLD.Traditional Chinese medicine is convenient to obtain and cheap.It can treat NAFLD through multiple channels with good clinical efficacy,and no obvious side effects have been found till now.Many studies have shown that traditional Chinese medicine can inhibit the occurrence and development of NAFLD by inhibiting the NF-κB signaling pathway.This article summarizes the research results of traditional Chinese medicine in treating NAFLD based on the NF-κB signaling pathway since 2021,for several traditional Chinese medicine extracts(flavonoids,terpenoids,polysaccharides,glycosides,alkaloids and phenolic compounds)and traditional Chinese medicine compound(Shugan Jianpi Fang,Erhuang Quzhi Granules,Fuzi Lizhong Decoction,Huangqin Decoction,Qinlian Hongqu Decoction,Jiangzhi Granules),which can inhibit the further development of NAFLD by improving liver inflammatory response,oxidative stress response,fibrosis,apoptosis,autophagy and pyroptosis through the NF-κB signaling pathway,in order to provide new ideas for future new drug development and clinical medication.
